NEW YORK, May 2, 2018 /PRNewswire/ — Pomerantz LLP is investigating claims on behalf of investors of Esperion Therapeutics, Inc. (“Esperion” or the “Company”)
ESPR, -35.11%
Such investors are advised to contact Robert S. …
Go to Source